Nimodipin Carinopharm (Nimodipine)

Nimodipine, the active ingredient in Nimodipin Carinopharm, is a calcium channel blocker presented as a sterile intravenous solution for intravenous use. It is employed to prevent cerebral vasospasm and improve cerebral blood flow after subarachnoid hemorrhage. GNH USA supplies Nimodipin Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine acts as a cerebral vasodilator and is used in neurocritical care to manage vascular complications after hemorrhagic events. - Subarachnoid hemorrhage (SAH): prevention of delayed cerebral ischemia caused by vasospasm. - Cerebral vasospasm: vasodilation to improve cerebral blood flow and reduce ischemic risk. - Neurocritical care: adjunct therapy to support cerebral perfusion in patients with SAH.

Nimodipine may cause a range of adverse reactions, most of which are related to its vasodilatory properties.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and reddening of skin. - Dizziness: sensation of light‑headedness. - Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Seizures: uncommon neurological event. - Pulmonary edema: fluid accumulation in lungs.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check for hypotension before and during infusion. - Cardiac status: evaluate for existing heart disease or arrhythmias. - Liver function: assess hepatic enzymes in patients with liver impairment. - Concomitant vasodilators: avoid additive hypotensive effects. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma levels, risking severe hypotension. - Other calcium channel blockers: additive vasodilatory effect leading to profound hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce nimodipine concentrations, diminishing therapeutic effect. - Antihypertensive agents (e.g., ACE inhibitors, beta‑blockers): may enhance blood pressure lowering. - Diuretics: increase risk of volume depletion and hypotension. - Nitrates: combined use can cause excessive vasodilation.